617 reports of this reaction
1.8% of all TOLTERODINE TARTRATE reports
#11 most reported adverse reaction
CONSTIPATION is the #11 most commonly reported adverse reaction for TOLTERODINE TARTRATE, manufactured by Viatris Specialty LLC. There are 617 FDA adverse event reports linking TOLTERODINE TARTRATE to CONSTIPATION. This represents approximately 1.8% of all 33,596 adverse event reports for this drug.
Patients taking TOLTERODINE TARTRATE who experience constipation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CONSTIPATION is a less commonly reported adverse event for TOLTERODINE TARTRATE, but still significant enough to appear in the safety profile.
In addition to constipation, the following adverse reactions have been reported for TOLTERODINE TARTRATE:
The following drugs have also been linked to constipation in FDA adverse event reports:
CONSTIPATION has been reported as an adverse event in 617 FDA reports for TOLTERODINE TARTRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CONSTIPATION accounts for approximately 1.8% of all adverse event reports for TOLTERODINE TARTRATE, making it a notable side effect.
If you experience constipation while taking TOLTERODINE TARTRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.